{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:42:36Z","timestamp":1777358556308,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03884-3","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T05:41:07Z","timestamp":1744436467000},"page":"3701-3706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSA reduction as predictor of biochemical relapse in low and favourable intermediate prostate cancer treated with radical radiotherapy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-4563","authenticated-orcid":false,"given":"Andrea Gaetano","family":"Allegra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-8041","authenticated-orcid":false,"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-0330","authenticated-orcid":false,"given":"Alessandro","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4693-2148","authenticated-orcid":false,"given":"Chiara","family":"De-Colle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-0319","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-827X","authenticated-orcid":false,"given":"Francesca","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Orsatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9978-7568","authenticated-orcid":false,"given":"Gabriella","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-3440","authenticated-orcid":false,"given":"Francesco","family":"Ricchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-0251","authenticated-orcid":false,"given":"Michele","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Romei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Zuccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-8628","authenticated-orcid":false,"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"1","key":"3884_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005.","journal-title":"Eur Urol"},{"issue":"17","key":"3884_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"issue":"1","key":"3884_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijrobp.2014.01.050","volume":"89","author":"S Swisher-McClure","year":"2014","unstructured":"Swisher-McClure S, Mitra N, Woo K, et al. Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89(1):103\u201312. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3884_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijrobp.2009.10.008","volume":"79","author":"C Proust-Lima","year":"2011","unstructured":"Proust-Lima C, Taylor JM, S\u00e9cher S, et al. Confirmation of a low \u03b1\/\u03b2 ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2011;79(1):195\u2013201. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"3884_CR5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325\u201332. https:\/\/doi.org\/10.1200\/JCO.2016.67.0448.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3884_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3884_CR7","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(19)30569-8.","journal-title":"Lancet Oncol"},{"key":"3884_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejmp.2020.09.026","volume":"80","author":"R Ruggieri","year":"2020","unstructured":"Ruggieri R, Rigo M, Naccarato S, et al. Adaptive SBRT by 1.5 T MR-linac for prostate cancer: on the accuracy of dose delivery in view of the prolonged session time. Phys Med. 2020;80:34\u201341. https:\/\/doi.org\/10.1016\/j.ejmp.2020.09.026.","journal-title":"Phys Med"},{"issue":"3","key":"3884_CR9","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.adro.2021.100865","volume":"7","author":"S Naccarato","year":"2022","unstructured":"Naccarato S, Rigo M, Pellegrini R, et al. Automated planning for prostate stereotactic body radiation therapy on the 1.5 T MR-Linac. Adv Radiat Oncol. 2022;7(3):100865. https:\/\/doi.org\/10.1016\/j.adro.2021.100865.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"3884_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ijrobp.2008.12.067","volume":"75","author":"MJ Zelefsky","year":"2009","unstructured":"Zelefsky MJ, Shi W, Yamada Y, et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys. 2009;75(5):1350\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.12.067.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"3884_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0360-3016(95)00137-N","volume":"32","author":"DA Kuban","year":"1995","unstructured":"Kuban DA, El-Mahdi AM, Schellhammer PF. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1995;32(2):307\u201316. https:\/\/doi.org\/10.1016\/0360-3016(95)00137-N.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"740","key":"3884_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","volume":"62","author":"JF Fowler","year":"1989","unstructured":"Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62(740):679\u201394. https:\/\/doi.org\/10.1259\/0007-1285-62-740-679.","journal-title":"Br J Radiol"},{"issue":"10","key":"3884_CR13","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s00432-019-02983-3","volume":"145","author":"L Nicosia","year":"2019","unstructured":"Nicosia L, Mazzola R, Rigo M, et al. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol. 2019;145(10):2547\u201354. https:\/\/doi.org\/10.1007\/s00432-019-02983-3.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10196","key":"3884_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet"},{"issue":"4","key":"3884_CR15","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.3390\/curroncol28040257","volume":"28","author":"MA G\u00f3mez-Aparicio","year":"2021","unstructured":"G\u00f3mez-Aparicio MA, Valero J, Caballero B, et al. Extreme hypofractionation with SBRT in localized prostate cancer. Curr Oncol. 2021;28(4):2933\u201349. https:\/\/doi.org\/10.3390\/curroncol28040257.","journal-title":"Curr Oncol"},{"key":"3884_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1748-717X-1-28","volume":"1","author":"AK Singh","year":"2006","unstructured":"Singh AK, Guion P, Susil RC, et al. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost. Radiat Oncol. 2006;1:28. https:\/\/doi.org\/10.1186\/1748-717X-1-28.","journal-title":"Radiat Oncol"},{"key":"3884_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2021.11.005","volume":"166","author":"TM Ma","year":"2022","unstructured":"Ma TM, Roy S, Wu X, et al. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: the phoenix definition and beyond. Radiother Oncol. 2022;166:1\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2021.11.005.","journal-title":"Radiother Oncol"},{"issue":"1","key":"3884_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.21873\/anticanres.15470","volume":"42","author":"R Iacovelli","year":"2022","unstructured":"Iacovelli R, Ciccarese C, Caffo O, et al. The role of fast and deep PSA response in castration-sensitive prostate cancer. Anticancer Res. 2022;42(1):165\u201372. https:\/\/doi.org\/10.21873\/anticanres.15470.","journal-title":"Anticancer Res"},{"issue":"27","key":"3884_CR19","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326. https:\/\/doi.org\/10.1056\/NEJMoa041588.","journal-title":"N Engl J Med"},{"issue":"3","key":"3884_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","volume":"79","author":"NK Jairath","year":"2021","unstructured":"Jairath NK, Dal Pra A, Vince R Jr, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. 2021;79(3):374\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.021.","journal-title":"Eur Urol"},{"key":"3884_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2022.02.016","volume":"169","author":"C Greco","year":"2022","unstructured":"Greco C, Pares O, Pimentel N, et al. Early PSA density kinetics predicts biochemical and local failure following extreme hypofractionated radiotherapy in intermediate-risk prostate cancer. Radiother Oncol. 2022;169:35\u201342. https:\/\/doi.org\/10.1016\/j.radonc.2022.02.016.","journal-title":"Radiother Oncol"},{"key":"3884_CR22","doi-asserted-by":"publisher","first-page":"110043","DOI":"10.1016\/j.radonc.2023.110043","volume":"190","author":"L Nicosia","year":"2024","unstructured":"Nicosia L, Ravelli P, Rigo M, et al. Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity. Radiother Oncol. 2024;190:110043. https:\/\/doi.org\/10.1016\/j.radonc.2023.110043.","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03884-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:11:15Z","timestamp":1756887075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03884-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03884-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filippo Alongi is consultant for Elekta and received speaker honoraria. Ruggero Ruggieri is scientific consultant for Elekta and received speaker honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study did not require ethics committee approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed an informed consent for collection of PSA values and treatment-related data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"For this type of study, formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}